Molbio Diagnostics Limited Q2 revenue fell during contract talks
Key highlights
- Molbio Diagnostics reported Q2 FY27 revenue from operations of Rs 259 crore, versus Rs 408 crore in Q1 FY27.
- Truenat test-kit revenue was Rs 197 crore in Q2 FY27, compared with Rs 374 crore in Q1 FY27.
- H1 FY27 revenue from operations was Rs 667 crore, versus Rs 680 crore in H1 FY26.
- Outside-India revenue accounted for 21% of Q2 FY27 revenue, compared with 7% in Q2 FY26.
powered by IRIS

Molbio Diagnostics Limited reported revenue from operations of Rs 259 crore in Q2 FY27, compared with Rs 408 crore in Q1 FY27 and Rs 580 crore in Q2 FY26, as management said rate-contract negotiations taking 1–1.5 months meant the quarter did not include a full three months of sales.
Know Molbio Diagnostics inside out
Results, valuation, peers and who's buying, in one view.
Why did Molbio Diagnostics' Q2 FY27 revenue decline?
Molbio Diagnostics said Q2 FY27 performance was softer because it was negotiating rate contracts, a process management said typically takes 1–1.5 months. Management said this shortened the sales period in the quarter, leaving revenue from operations at Rs 259 crore, Rs 149 crore below the Rs 408 crore reported in Q1 FY27.
The largest movement was in Truenat test kits, which generated Rs 197 crore in Q2 FY27, versus Rs 374 crore in Q1 FY27 and Rs 518 crore in Q2 FY26. Test kits were also the main recurring product category in FY26, when they represented 73.98% of product revenue, so their Rs 177 crore sequential decline had the largest effect on quarterly revenue.
Molbio Diagnostics characterised its business as non-linear and said quarterly performance can vary. The supplied presentation does not report Q2 FY27 profit, profit margin, earnings before interest, tax, depreciation and amortisation, or EBITDA, or a 93% change in profit; it therefore supports a revenue analysis rather than a quantified conclusion on quarterly profit.
How did Molbio Diagnostics' product mix change in Q2 FY27?
Molbio Diagnostics' smaller product lines increased or held up better than Truenat test kits in Q2 FY27, but did not offset the lower kit sales. Truenat devices rose to Rs 31 crore from Rs 15 crore in Q1 FY27, while services or other revenue increased to Rs 18 crore from Rs 8 crore.
Prognosys radiology generated Rs 9 crore in Q2 FY27, below Rs 11 crore in Q1 FY27 but above Rs 6 crore in Q2 FY26. OptraSCAN digital pathology contributed Rs 5 crore, compared with Rs 1 crore in Q1 FY27 and nil in Q2 FY26, showing growth from a smaller revenue base.
For H1 FY27, Truenat test-kit revenue reached Rs 570 crore, compared with Rs 562 crore in H1 FY26. The first-quarter contribution of Rs 374 crore meant first-half kit sales were Rs 8 crore higher year on year despite Q2 FY27 revenue of Rs 197 crore.
What did Molbio Diagnostics report for H1 FY27?
Molbio Diagnostics reported H1 FY27 revenue from operations of Rs 667 crore, compared with Rs 680 crore in H1 FY26, a difference of Rs 13 crore. Management separately reported total income of Rs 676.3 crore for H1 FY27 against Rs 681.8 crore in H1 FY26, which is a different measure from revenue from operations.
The half-year comparison was narrower than the quarterly change: Q2 FY27 revenue from operations was Rs 321 crore below Q2 FY26, while H1 FY27 revenue was Rs 13 crore below H1 FY26. Management said H1 has historically accounted for around 35–45% of full-year revenue, while maintaining its FY27 objective of 25% topline growth over FY26.
Radiology increased by Rs 9 crore year on year in H1 FY27, and OptraSCAN added Rs 6 crore from a nil base. Those gains were outweighed by a Rs 23 crore decline in Truenat devices and a Rs 12 crore decrease in services or other revenue, while the presentation does not disclose profit by product line.
Got a follow-up? Ask IRIS
Where did Molbio Diagnostics' Q2 FY27 revenue come from?
Molbio Diagnostics derived 79% of Q2 FY27 revenue from India and 21% from outside India. The domestic share was 83% in Q1 FY27 and 93% in Q2 FY26, while the outside-India share rose from 17% sequentially and 7% year on year.
For H1 FY27, India represented 81% of revenue and outside India represented 19%, compared with 92% and 8%, respectively, in H1 FY26. The presentation says Truenat had a presence in more than 90 countries and that more than 12,500 Truenat devices had been sold, but it does not provide country-level sales figures.
Truenat is described as a portable, battery-operated real-time polymerase chain reaction, or PCR, platform. Molbio Diagnostics reported 43 assays covering 30 diseases and 17.6 million test kits sold in FY26, but the presentation does not state whether the Q2 FY27 geographic shift came from a specific product, country or contract.
What is Molbio Diagnostics planning for FY27?
Molbio Diagnostics management said it remains committed to working towards 25% topline growth in FY27 over FY26, when total income was Rs 1,455 crore. This is management's stated objective rather than a reported outcome, and the presentation provides no quarterly revenue forecast or contract-renewal timetable.
Management said it is in advanced stages of developing new platforms for laboratories, hospitals and doctors' clinics. It also said radiology products are being deployed for veterinary use and that six veterinary assays are under development for Truenat devices, without providing launch dates or expected FY27 revenue.
Research and development spending was Rs 87.5 crore in FY26, compared with Rs 68.6 crore in FY25 and Rs 59.8 crore in FY24. Molbio Diagnostics also reported 153 research and development professionals, including 136 scientists, and 207 registered patents, although the presentation gives no commercial forecast for the new platforms or veterinary assays.
Conclusion
Molbio Diagnostics' Q2 FY27 presentation attributes the revenue decline to the timing of rate-contract negotiations: revenue from operations fell to Rs 259 crore and Truenat test-kit revenue fell to Rs 197 crore. First-half revenue from operations, at Rs 667 crore versus Rs 680 crore a year earlier, shows that the H1 movement was substantially smaller than the Q2 decline.
The next disclosures to watch are the revenue pattern after rate-contract negotiations and management's progress towards its stated FY27 target of 25% topline growth over FY26. Molbio Diagnostics' plan to develop six veterinary assays and new laboratory platforms is also relevant, but the presentation does not disclose launch schedules or expected sales contributions.


